Get the Stockscreener App
49.32
0.46%
-0.23
After Hours:
49.32
Scholar Rock Holding Corp stock is traded at $49.32, with a volume of 1.26M.
It is down -0.46% in the last 24 hours and up +23.27% over the past month.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
See More
Previous Close:
$49.55
Open:
$49.74
24h Volume:
1.26M
Relative Volume:
0.94
Market Cap:
$5.67B
Revenue:
$47.30M
Net Income/Loss:
$-377.94M
P/E Ratio:
-14.40
EPS:
-3.4256
Net Cash Flow:
$-300.64M
1W Performance:
-1.34%
1M Performance:
+23.27%
6M Performance:
+52.22%
1Y Performance:
+63.20%
1-Day Range:
$48.91
$49.96
1-Week Range:
$48.51
$50.55
52-Week Range:
$27.07
$51.62
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Name
Scholar Rock Holding Corp
Sector
Industry
Phone
857-259-3860
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
49.32 | 5.69B | 47.30M | -377.94M | -300.64M | -3.4256 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Citigroup | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-09-25 | Initiated | BofA Securities | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Resumed | Jefferies | Buy |
| Jul-30-25 | Resumed | Raymond James | Strong Buy |
| Jul-17-25 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-26-24 | Reiterated | H.C. Wainwright | Buy |
| Oct-07-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-24 | Initiated | Raymond James | Strong Buy |
| Oct-25-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Overweight |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jul-12-22 | Initiated | Truist | Buy |
| Mar-23-22 | Initiated | H.C. Wainwright | Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Mar-12-20 | Initiated | Robert W. Baird | Outperform |
View All
Scholar Rock Holding Corp Stock (SRRK) Latest News
SRRK: Analyst Maintains Rating but Lowers Price Target to $44 | - GuruFocus
SRRK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
SRRK Technical Analysis | Trend, Signals & Chart Patterns | SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK) - ChartMill
Scholar Rock stock hits 52-week high at 51.31 USD By Investing.com - Investing.com India
Scholar Rock (NASDAQ:SRRK) Reaches New 52-Week HighWhat's Next? - MarketBeat
Scholar Rock stock hits 52-week high at 51.31 USD - Investing.com
A Look At Scholar Rock (SRRK) Valuation After Apitegromab BLA Resubmission And Reduced Regulatory Risk - Sahm
Scholar Rock Holding Corporation (SRRK) stock price, news, quote and history - Yahoo Finance Singapore
Mohammed Qatanani (NASDAQ: SRRK) files Form 144 to sell 23,408 shares via option exercise - Stock Titan
Scholar Rock (SRRK) Deepens SMA Manufacturing Footprint: Strategic Resilience Move or Regulatory Risk Signal? - Yahoo Finance
Scholar Rock to rally around 18%? Here are 10 top analyst forecasts for Wednesday - MSN
SRRK Stock Surges To Near Five-Year Highs – Here’s Why Analysts Are Bullish About Its Latest FDA Filing - Stocktwits
SG Americas Securities LLC Has $3.72 Million Stock Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
SRRK News | SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK) - ChartMill
Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
Jefferies raises Scholar Rock stock price target on BLA resubmission - Investing.com UK
Jefferies raises Scholar Rock stock price target on BLA resubmission By Investing.com - Investing.com South Africa
SRRK Stock: Wedbush Raises Price Target to $58, Maintains Outper - GuruFocus
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug - Yahoo Finance
Wedbush Forecasts Strong Price Appreciation for Scholar Rock (NASDAQ:SRRK) Stock - MarketBeat
Scholar Rock (NASDAQ:SRRK) Sets New 12-Month HighShould You Buy? - MarketBeat
Scholar Rock Resubmits Apitegromab BLA to FDA for Spinal Muscular Atrophy Treatment, Anticipates Approval in Late 2026 123 - Minichart
Scholar Rock Resubmits Apitegromab BLA for SMA, Adds Second Fill-Finish Site; FDA Decision Eyed by Sept. - MarketBeat
Why Scholar Rock Holding (SRRK) Is Up 16.2% After Apitegromab BLA Resubmission With FDA-Aligned Manufacturing - simplywall.st
Scholar Rock Holding Corp stock hits 52-week high at 49.98 USD - Investing.com Australia
Scholar Rock resubmission ‘material de-risking event,’ says H.C. Wainwright - TipRanks
Scholar Rock (SRRK) Resubmits Key Application, Stock Climbs - GuruFocus
Scholar Rock (SRRK) Stock Surges 15.5% - GuruFocus
Scholar Rock (SRRK) Shares Rise Following BLA Resubmission - GuruFocus
Scholar Rock (NASDAQ:SRRK) Shares Gap UpHere's Why - MarketBeat
Scholar Rock (SRRK) Resubmits BLA for Apitegromab Targeting SMA - GuruFocus
Scholar Rock stock surges on FDA resubmission for SMA drug By Investing.com - Investing.com UK
Scholar Rock (SRRK) resubmits apitegromab BLA with FDA, eyes Sept 2026 decision - Stock Titan
Biopharmaceutical company Scholar Rock Holding Corp (SRRK) recently announced that regarding the resubmission of its Biologics License Application (BLA), the company expects the U.S. Food and Drug Administration (FDA) to accept the filing within 30 d - Bitget
Scholar Rock resubmits apitegromab application to FDA By Investing.com - Investing.com UK
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) - ChartMill
A Look At Scholar Rock Holding (SRRK) Valuation As Growth Expectations Face Mixed Share Price Signals - Yahoo Finance
Is Scholar Rock Holding (SRRK) Still Attractive After Recent Share Price Pullback? - simplywall.st
Scholar Rock: From Manufacturing Hurdle To Commercial Muscle, Maintaining Buy Rating (NASDAQ:SRRK) - Seeking Alpha
Vanguard disaggregates holdings, reports 0 shares for Scholar Rock (SRRK) - Stock Titan
E. Ohman J or Asset Management AB Has $721,000 Stake in Scholar Rock Holding Corporation $SRRK - MarketBeat
JPMorgan Chase & Co. Buys 440,401 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
SRRK PE Ratio & Valuation, Is SRRK Overvalued - Intellectia AI
Stocks flashing renewed technical strength: Scholar Rock Holding - MSN
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT) - The Globe and Mail
Scholar Rock Holding Corp Stock (SRRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):